Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bifeprunox · 4 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Bifeprunox | DRUG | - |
| bifeprunox, olanzapine | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Outpatients who have successfully completed Wyeth study 3168A1-311-US. 2. A signed and dated informed consent form for this study. 3. No major protocol violations in previous study. Exclusion Criteria: 1. Clinically important abnormalities noted in preceding short-term stud...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Bifeprunox was developed for the treatment of schizophrenia, bipolar disorder, and bipolar depression. It is a small molecule psychiatric drug that reached Phase 3 clinical testing. All of its recorded trials are completed, and it is not currently listed as an approved medicine.
Bifeprunox targets the serotonin 5-HT1A receptor (HTR1A) and the dopamine D2 receptor (DRD2). It acts as a partial agonist at these receptors, meaning it produces a moderated rather than full activation signal. This dual receptor activity is the basis for its proposed antipsychotic and mood-stabilizing effects.
Bifeprunox was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 3 clinical program evaluating the compound in schizophrenia and bipolar depression.
Bifeprunox reached Phase 3 clinical development. It is an investigational drug and is not approved for marketing. Its registered trials are all listed as completed, and no trials are currently active.
Bifeprunox was studied in completed Phase 3 trials including NCT00380224, which compared bifeprunox with olanzapine on weight in outpatients with schizophrenia, NCT00366171, an open label extension study, and NCT00245973 and NCT00134459, both evaluating bifeprunox in bipolar depression.
No. Bifeprunox and olanzapine are different drugs. Bifeprunox was developed by Pfizer as a partial agonist at HTR1A and DRD2. Olanzapine appears in the bifeprunox program as an active comparator in a Phase 3 schizophrenia trial, NCT00380224, which assessed weight effects during treatment.